Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Amgen (NQ: AMGN )

283.61 -12.32 (-4.16%)
Streaming Delayed Price Updated: 4:00 PM EST, Nov 15, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Amgen

< Previous 1 2
...
30 31 32 33 34 35 36 37 38
...
47 48 Next >
4 Index Funds to Buy and Hold Forever
These are the best index funds to buy and hold in August. DIA, ONEQ, RYF and XSD can make great long-term investments. 
Via InvestorPlace
This Is What Whales Are Betting On Amgen
  A whale with a lot of money to spend has taken a noticeably bullish stance on Amgen. Looking at options history for Amgen (NASDAQ:AMGN) we detected 10 strange trades. 
Via Benzinga
Karuna Therapeutics To $276? Plus SVB Leerink Almost Doubles Price Target On This Stock
Mizuho boosted the price target for Karuna Therapeutics, Inc. (NASDAQ: KRTX) from $190 to $276. Karuna Therapeutics shares fell 1.3% to $238.00 in pre-market trading. 
Via Benzinga
Amgen's Lumakras/Keytruda/Tecentriq Combo Data Flags Safety Concern
Via Benzinga
Analyst Ratings for Amgen
Analysts have provided the following ratings for Amgen (NASDAQ:AMGN) within the last quarter: 
Via Benzinga
Amgen Q2 Earnings and Revenues Beat Estimates
Amgen came out with quarterly earnings of $4.65 per share. 
Via Talk Markets
ChemoCentryx Stock More Than Doubles On $4B Buyout
Via Benzinga
Two Appealing Biotech Stocks for Two Distinct investors
Investing in biotech stocks carries both risk and reward. This article highlights two biotech companies that may appeal to specific investing styles 
Via MarketBeat
Topics Intellectual Property
Exposures COVID-19 Intellectual Property
Small Cap Biotechs Perk Up On Dealmaking
With M&A picking up we would think smaller deals make sense for large cap biopharma to expand pipelines and complement technology. 
Via Talk Markets
Amgen's Q2 Sales Impacted By Lower Prices, Currency Headwind, Reaffirms FY22 Outlook
Via Benzinga
What Are Whales Doing With Amgen
Someone with a lot of money to spend has taken a bearish stance on Amgen (NASDAQ:AMGN). And retail traders should know. We noticed this today when the big position showed up on publicly available... 
Via Benzinga
Amgen Narrows Sales Outlook Following Plans To Acquire ChemoCentryx
The company also reported a second-quarter beat and reiterated its earnings outlook. 
Via Investor's Business Daily
Stock Market Rally Mixed As Oil Prices Fall, Job Growth Hot: Weekly Review
The Nasdaq and small caps rose while the S&P 500 is hitting resistance. 
Via Investor's Business Daily
Recap: Amgen Q2 Earnings
Amgen (NASDAQ:AMGN) reported its Q2 earnings results on Thursday, August 4, 2022 at 04:02 PM. Here's what investors need to know about the announcement. Earnings Amgen beat estimated earnings by 5.68%,... 
Via Benzinga
ChemoCentryx Shares Are Jumping 110% Thursday: Here's Why
Shares of ChemoCentryx, Inc. (NASDAQ: CCXI) are skyrocketing Thursday following a groundbreaking announcement for the biopharmaceutical company. Why Is It Moving? 
Via Benzinga
ChemoCentryx (NASDAQ: CCXI) to be Acquired by Amgen (NASDAQ: AMGN) for $3.7 Billion in Cash
ChemoCentryx, Inc. (NASDAQ: CCXI) is engaged as a biopharmaceutical company that is focused on the research, development and commercialization of 
Via Spotlight Growth
ChemoCentryx (CCXI) Stock Soars 100% on Amgen Acquisition
ChemoCentryx (CCXI) stock is rocketing higher on Thursday as investors react to news of an acquisition deal with Amgen (AMGN). 
Via InvestorPlace
Amgen Plans $3.7 Billion ChemoCentryx Buyout, Tapping Into A New Market
The company will pay $52 per share to buy ChemoCentryx, a rare disease-focused firm. 
Via Investor's Business Daily
Biotech Daily: Amgen, Gilead Go Shopping, Nod For AstraZeneca's Lynparza In Early Stage Breast Cancer, Decision Day For Alzheimer's Associated Hallucinations Candidate
Here's a roundup of top developments in the biotech space over the last 24 hours: 
Via Benzinga
Oil Falls Amid Rise In Reserves, China Is Creating A Blockade On Taiwan
Crude oil inventories unexpectedly rose by 4.5 million barrels last week, compared to analysts' forecast of 600,000 barrels. The OPEC+ group said it would raise its oil production target by just... 
Via Talk Markets
Equity Index Futures Rebound Despite Concerns Over OPEC And China
(Wednesday Market Open) Stocks look to rebound as equity index futures point to a higher open and the dollar retreats from yesterday’s rally. But Fed speak and news out of OPEC and China present... 
Via Benzinga
Don’t Mess With The IRS
If we've learned anything from the likes of Al Capone, it’s that you don’t want to mess with the IRS. That’s especially true when Amgen may be the first target in an aggressive campaign to clamp down... 
Via Talk Markets
10 Highest Yielding Dow Jones Stocks: Which Stocks Pay Out 3.2% To 5.5% To Investors?
Created in 1896 by Charles Dow, the Dow Jones Industrial Average is one of the oldest and most followed equity indexes for overall stock market health. The Dow Jones Industrial Average consists of 30... 
Via Benzinga
U.S. Manufacturing Picture Is Looking Brighter Than Europe's Right Now
(Tuesday Market Open) Global jitters over U.S. House Speaker Nancy Pelosi’s expected visit to Taiwan dominated premarket trading with major U.S. equities indexes moving mildly lower before the open.... 
Via Benzinga
Is The Energy Ready To Rebound?
(Monday Market Open) Equity index futures turned a bit negative to start a new week and month, as investors are still digesting last week’s data with the S&P 500® index (SPX) near June highs. 
Via Benzinga
Benzinga Before The Bell: Alibaba's Delisting Concerns, Amgen's Potential $10.7B Tax Bill, Kenya Will Not Shut Facebook Services And Other Top Financial Stories Monday, August 1
CNBC 
Via Benzinga
Amgen To Fight IRS Agency Over Tax Bill Of Whooping $10.7B: Report
Via Benzinga
Biotech Investors: August's Key PDUFA Catalysts You Must Know
Regulatory decisions have yet to pick up pace this year. July’s calendar was light, but the good news was that most decisions turned out to be positive. That said, none of the drugs approved during the... 
Via Benzinga
Big Tech Continues To Rally Despite Earnings Misses
(Friday Market Open) Equity index futures pointed to a higher open as investors looked to wrap up the week and month on a positive note, but a higher-than-expected inflation report pushed the dollar... 
Via Benzinga
Meta and Qualcomm Miss— Will Tech Investors Shrug Off These Reports Too?
(Thursday Market Open) Investors might be ready to take a breather after yesterday’s Fed rate rally, but with slower second-quarter GDP numbers and even more earnings and global economic data arriving... 
Via Benzinga
< Previous 1 2
...
30 31 32 33 34 35 36 37 38
...
47 48 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.